FDA approves first interchangeable biosimilar product for Humira

Oct 18, 2021 - 01:15 PM
FDA product update

The Food and Drug Administration today approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases. The product (Cyltezo) is approved to treat certain adult and pediatric patients with arthritis or Crohn’s disease, and certain adults with ulcerative colitis or psoriasis. 

Related News Articles

Headline
FDA evaluating certain plastic syringes made in China
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…
Headline
FDA announces Class I ventilator recall for Draeger product’s pediatric use
Draeger Medical, Inc. is recalling its Carina Ventilators due to the presence of contaminants in the device’s airpath, which exceed acceptable levels if…
Headline
Pfizer issues update on sterile injectables plant struck by tornado
Crews are working to restore power and assess damage to a Pfizer plant in North Carolina that makes sterile injectables for U.S. hospitals after a tornado…
Headline
Agencies target unapproved pharmaceutical products from India
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
Agencies seek information on medical payment products
The Consumer Financial Protection Bureau, Centers for Medicare & Medicaid Services, Department of Health and Human Services, and Department of the Treasury…
Headline
FDA releases guidance to help hospitals conserve pneumatic tourniquet cuffs
As urged by the AHA and its professional membership group the Association for Health Care Resource & Materials Management, the Food and Drug Administration…